Table 2

Patient demographics

No. of patientsMedian (range)
Total no. entered (males/females)65 (32:33)
Age (yr)53 (34–75)
Body surface area (m2)1.86 (1.29–2.36)
Performance score1 (0–1)
Ethnicity
 European Caucasian63
 Asian2
Tumor types
 Gastrointestinal49
 (Adeno-) carcinoma of unknown primary7
 Miscellaneous9a
Clinical chemistry
 AST/ALT < 3 × ULNb60
 AST/ALT 3 to 5 × ULN5
 Bilirubin < ULN62
 Bilirubin 1 to 1.5 × ULN3
 Creat < ULN/creat CL > LLN59
 Creat < 135 μmol/l/creat CL > 60 ml/min6
Irinotecan dose
 200–230 mg/m26
 250–300 mg/m28
 350 mg/m251
Concomitant medication
 Cisplatin3
 None62
  • a Pancreas (five), lung (two), cervix (two).

  • b ULN, upper limit of normal; Creat, creatinine; LLN, lower limit of normal.